Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 versus placebo in idiopathic pulmonary fibrosis
NL-OMON55951Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change from baseline in forced vital capacity at Week 52. Started Mar 2023; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON55951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55951.